Navigation Links
Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer
Date:10/3/2007

BOULDER, Colo., Oct. 3 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (Nasdaq: TPPH) announced today that it has initiated a Phase 2 open- label, multi-center study of TPI 287 in patients with advanced pancreatic cancer. This is the second Phase 2 trial exploring the activity of TPI 287 in various tumor types: the first Phase 2 trial began earlier this year in advanced hormone refractory prostate cancer.

"Currently available taxanes are not approved for pancreatic cancer and effective treatment options for this difficult tumor are quite limited," commented Leonard Shaykin, chairman and chief executive officer of Tapestry Pharmaceuticals. "This pancreatic trial, combined with our experience in both the Phase 1 and in the Phase 2 trial currently running in refractory prostate cancer, will further characterize the safety and efficacy profile of TPI 287 in classically resistant and hard to treat tumors."

Trial Design

The pancreatic cancer trial for TPI 287 is a multi-center, open-label, single arm Phase 2 study for up to 65 patients with advanced stage, unresectable pancreatic cancer who have failed a prior gemcitabine-containing chemotherapy regimen for their disease. The trial will be conducted in approximately 10 to 15 centers in the U.S., Europe and India. Patients will receive TPI 287 administered as a 60 minute (+/- 10 min) IV infusion.

The primary endpoint of the trial will be the six-month survival (percent of patients alive at six months after starting the study). Secondary efficacy endpoints will be the six-month progression free survival (percent of patients whose disease has not advanced by six months), response to therapy (reduction in radiographically measurable disease as d
'/>"/>

SOURCE Tapestry Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Tapestry Pharmaceuticals to Present Data on TPI 287 at the 2007 AACR Annual Meeting
2. Malvern initiates European user group meetings for chemical imaging
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... AVIV, Israel , May 6, 2015  Galmed ... biopharmaceutical company focused on the development and commercialization of ... diseases and cholesterol gallstones, announced today that it will ... 13, 2015 to discuss results for the period ended ... current developments with respect to its clinical program for ...
(Date:5/6/2015)... , May 6, 2015 Neuralstem, Inc. (NYSE ... technology to develop small molecule and cell therapy treatments ... Jonathan Lloyd Jones to the position of ... Mr. Lloyd Jones brings to ... and business development experience.   Most recently, Mr. Lloyd ...
(Date:5/6/2015)... BOSTON, May 6, 2015  Juniper Pharmaceuticals, Inc. (Nasdaq: ... financial results for the three-month period ended March 31, ... were $8.3 million, an increase of 19% as compared ... , Product revenues increased 41% year-over-year, enabled by ... shipments to Merck Serono in the fourth quarter of ...
Breaking Medicine Technology:Galmed Pharmaceuticals First Quarter 2015 Conference Call and Webcast Scheduled for Wednesday, May 13, 2015 2Galmed Pharmaceuticals First Quarter 2015 Conference Call and Webcast Scheduled for Wednesday, May 13, 2015 3Neuralstem Appoints Jonathan Lloyd Jones as Chief Financial Officer 2Neuralstem Appoints Jonathan Lloyd Jones as Chief Financial Officer 3Neuralstem Appoints Jonathan Lloyd Jones as Chief Financial Officer 4Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 2Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 3Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 4Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 5Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 6Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 7Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 8Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 9Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 10Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 11
(Date:5/6/2015)... GA (PRWEB) May 06, 2015 ... chosen Hexagon Geospatial technology to manage and distribute imagery, ... Australia is one of the driest continents on earth, ... through times of drought and erratic seasonal rainfalls has ... supply solutions. , Water NSW manages raw water supplies ...
(Date:5/6/2015)... The GUARDaHEART Foundation was proud to work ... the mission of providing basic living essentials and health ... Thursday, April 30th. , Through its partnership with ... the early-detection and diagnosis of heart disease, GUARDaHEART was ... to homeless individuals and families. , “Heart Disease ...
(Date:5/6/2015)... CA (PRWEB) May 06, 2015 ... program - today announced the latest lineup of speakers ... Summit . The invitation-only event, scheduled for May 18-19 ... senior care executives, consumer technology leaders, investors and more ... emerging trends, cultivate partnerships and discover new products and ...
(Date:5/6/2015)... Established by the Arthritis Foundation, the ... 46 million Americans who suffer from arthritis. Many who ... alleviate their symptoms. Medicationdiscountcard.com is proud to offer a ... on the costs of these necessary prescriptions. , Non-Steroidal ... the pain and inflammation in the joints associated with ...
(Date:5/6/2015)... May 06, 2015 Qualidigm ... Conn., has hired healthcare executive Ann Olson, RN, ... Olson will lead Qualidigm’s growing home healthcare services ... to improve the quality, safety, and cost-effectiveness of ... Qualidigm from Interim HealthCare of North Haven, Inc., ...
Breaking Medicine News(10 mins):Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 2Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 3Health News:GUARDaHEART and Starbucks® Collaborate for Impactful Event to Help Homeless Families 2Health News:Aging2.0 Global Innovation Summit Provides Unique Forum to Discover New Technologies and Develop Partnerships in the Senior Care Market 2Health News:Aging2.0 Global Innovation Summit Provides Unique Forum to Discover New Technologies and Develop Partnerships in the Senior Care Market 3Health News:Aging2.0 Global Innovation Summit Provides Unique Forum to Discover New Technologies and Develop Partnerships in the Senior Care Market 4Health News:Medicationdiscountcard.com Provides Access to Drug Coupons for Arthritis Awareness Month 2Health News:Medicationdiscountcard.com Provides Access to Drug Coupons for Arthritis Awareness Month 3Health News:Innovative Healthcare Executive Ann Olson Joins Qualidigm as Principal and Vice President 2Health News:Innovative Healthcare Executive Ann Olson Joins Qualidigm as Principal and Vice President 3
... Rice political scientists Mark Jones and William Reed with ... aberrations in the use of Tasers related to ethnicity, ... Statistical Analysis of the Use of Conducted Energy Devices ... a larger report, "Conducted Energy Device Program Performance Audit," ...
... Inc., the first,company to commercialize human embryonic stem ... of former Serologicals,Corporation CFO, Harold "Bud" Ingalls, to ... ), Mr. Ingalls brings over 40 ... experience as a chief financial officer to ArunA,s,Board. ...
... WebMD ... Va., Sept. 9 comScore, Inc. (Nasdaq:,SCOR), a leader in ... that the health information site category has grown 21,percent during ... rate of the,total U.S. Internet population., (Logo: http://www.newscom.com/cgi-bin/prnh/20080115/COMSCORELOGO ...
... they may underestimate intensity of future urge to light up ... craving a hit of nicotine the moment you declare you ... say researchers at the University of Pittsburgh and Carnegie Mellon ... of smoking a cigarette becomes increasingly attractive to smokers while ...
... experts including the BPC,s Leaders,Project on the State ... McClellan, WASHINGTON, Sept. 9 The Bipartisan ... will host a policy,forum in support of the ... titled, "Achieving High-Value Health Care: Practical Lessons for,Health ...
... Sept. 9 Entire villages have,been washed away in ... monsoon rains and a dam burst caused a deluge ... Fund for Animal,Welfare -- http://www.ifaw.org ) deployed an ... treated and fed over 6000 starving livestock that,escaped the ...
Cached Medicine News:Health News:Rice political scientists co-author report on ethnic/racial aspects of Taser use by Houston police 2Health News:ArunA Biomedical Names Harold Ingalls to its Board of Directors 2Health News:Online Health Information Category Grows at Rate Four Times Faster Than Total Internet 2Health News:Online Health Information Category Grows at Rate Four Times Faster Than Total Internet 3Health News:Online Health Information Category Grows at Rate Four Times Faster Than Total Internet 4Health News:Study Probes Why Smokers Find It Hard to Quit 2Health News:Senator George Mitchell and the Bipartisan Policy Center to Host Forum Examining Health Insurance Reform 2Health News:Senator George Mitchell and the Bipartisan Policy Center to Host Forum Examining Health Insurance Reform 3Health News:Animal Rescue Operations Underway in Flooded Bihar, India 2Health News:Animal Rescue Operations Underway in Flooded Bihar, India 3
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Inquire...
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
... The new Finnpipette Focus ... specifically to combine ergonomics with ... interchangeable handle plate offers a ... sizes. The new shorter tip ...
Medicine Products: